Recent News

EHA2021: ALPINE Trial of Zanubrutinib Versus Ibrutinib in Resistant CLL

EHA2021: Phase III GLOW Trial of Ibrutinib and Venetoclax as First-Line CLL Therapy

ASCO 2021: Fixed-Duration Treatment With Ibrutinib Plus Venetoclax in CLL

ASCO 2021: Phase III Noninferiority Trial of Acalabrutinib Versus Ibrutinib in CLL

Richter’s Transformation in CLL: B-Cell Receptor Signals and Genetic Lesions

Impact of Ibrutinib on T-Cell Responses in CLL

Rare Case of Metastatic CLL Presenting as Focal Mass in the Gallbladder

Deletion 17p Subclones and Outcomes in Patients With CLL

FDA Brief: New Drug Application Accepted for CD20-Targeted CAR T-Cell Therapy for CLL

Genetic Relationship Between CLL and Non-Melanoma Skin Cancer?

Does Ibrutinib Therapy Induce Host Antitumor Immune Activation in CLL?

Potential Biomarkers in CLL Harboring Trisomy 12 Under Study

Case Study: Rare Richter Transformation of CLL Involving the Ear

Untangling Neutrophil Clues to Increased Bacterial Infections in CLL

Serum APRIL Levels: Novel Prognostic Marker Under Study in CLL

Rare Case of Acute Macular Neuroretinopathy in a Woman With CLL

AACR 2021: T-Cell Infusion Product Under Investigation in Resistant CLL

Concurrent Adenoid Cystic Carcinoma and CLL: Case Report

Response to Induction Therapy and Ofatumumab Consolidation in Patients With CLL

Identifying Prognostic Markers for Early-Stage CLL

Novel Agent Under Study in CLL: Dual Inhibitory Activity Reported

High-Risk CLL: GENUINE Trial of Ublituximab Plus Ibrutinib Versus Ibrutinib Alone

BTK Inhibitor and Cerebral Invasive Aspergillosis: Case Report in CLL

Toxicity and Treatment Discontinuation in CLL: U.S. Veterans Health Administration Study

Successful Addition of a New Treatment Arm to the Phase III FLAIR Trial in CLL

Subclinical Coagulopathy Associated With Obinutuzumab Infusion for CLL?

Preclinical Study of Combination Therapy for CLL: Avadomide Plus Checkpoint Inhibition

Case Report in CLL: Is Sclerouveitis an Off-Target Effect of Ibrutinib Treatment?

Blood Clots: New Adverse Event With First Infusion of Obinutuzumab for CLL?

Case Study: Personalized Low-Dose Immunotherapy for Poor-Prognosis CLL

Ibrutinib Versus Idelalisib Plus Rituximab in Resistant CLL

Blood Eosinophil Count and Prognosis in CLL

TCT 2021: Case of Accelerated-Phase CLL/SLL Relapsing as PTCL After Transplantation

TCT 2021: Update on Transplant Outcomes for CLL in Australasia

Case Report: CLL With Right Temporal Lobe Tumor

Reports of Rare Translocation in Chinese Patients With CLL

Using a Whole-Blood Loop Assay to Characterize Immune Response to Rituximab

COVID-19 and CLL: A Spanish Perspective

Pilot Study of Rituximab Biosimilar in Newly Diagnosed CLL

Novel STAT3 Inhibitor Under Study in CLL

Does Idelalisib Increase the Risk of Bleeding Events in Patients With CLL?

Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update

Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL

FDA Brief: Rituximab Biosimilar Approved for Treatment of CLL

ASH 2020: 5-Year Update From MURANO on Venetoclax Versus Bendamustine in Resistant CLL